Related Experiment Videos
[Clinical study on cefteram pivoxil in asymptomatic bacteriospermia]
1Department of Obstetrics and Gynecology, School of Medicine, Yamagata University.
The Japanese Journal of Antibiotics
|May 1, 1991
Summary
Cefteram pivoxil (CFTM) demonstrates measurable semen concentrations after oral administration, with varying in vitro activity against common bacteria. Further research is needed to confirm its clinical efficacy for asymptomatic bacteriospermia.
Area of Science:
- Pharmacology
- Microbiology
- Urology
Background:
- Asymptomatic bacteriospermia requires effective antibiotic treatment.
- Understanding antibiotic penetration into semen is crucial for treatment efficacy.
Purpose of the Study:
- To evaluate the clinical efficacy of cefteram pivoxil (CFTM) for asymptomatic bacteriospermia.
- To determine CFTM concentrations in human semen after oral administration.
- To assess the in vitro activity of CFTM, cefaclor (CCL), and lomefloxacin (LFLX) against bacteria found in semen.
Main Methods:
- Oral administration of 200 mg CFTM to healthy adults (n=5) and measurement of semen concentrations.
- Retrospective analysis of antibiotic activity against 65 bacterial strains (11 aerobic, 48 anaerobic) isolated from semen.
- Comparison of CFTM, CCL, and LFLX activity against anaerobic bacteria, including Peptostreptococcus sp.
Main Results:
- CFTM semen concentrations peaked at 0.66 +/- 0.04 microgram/ml at 5 hours post-administration.
- CFTM showed greater in vitro activity against anaerobic bacteria compared to CCL and LFLX.
- Lomefloxacin exhibited higher activity than cefaclor against Peptostreptococcus sp.
Conclusions:
- CFTM achieves detectable levels in semen, suggesting potential for treating genitourinary infections.
- In vitro activity data indicates CFTM may be effective against certain anaerobic bacteria.
- Further studies are necessary to optimize antibiotic selection and administration for asymptomatic bacteriospermia, considering semen penetration and bacterial susceptibility.